The Effect of Metformin Treatment on Non-Alcoholic Fatty Pancreas and Liver Disease in New-Onset Diabetes Mellitus by Zsóri, Gábor et al.
J Dig Dis Hepatol, an open access journal
ISSN: 2574-3511
1 Volume 2018; Issue 01
Journal of Digestive Diseases and Hepatology
Research Article
Zsóri G, et al. J Dig Dis Hepatol: JDDH-144.
The Effect of Metformin Treatment on Non-Alcoholic Fatty Pan-
creas and Liver Disease in New-Onset Diabetes Mellitus
Gábor Zsóri1*, Klára Kosár1, Gábor Holzinger1, Dóra Illés1, Emese Ivány1, Géza Szabovik2, Máté Tajti1, András Nagy2, András 
Palkó2, László Czakó1
1University of Szeged, Faculty of Medicine, Albert Szent-Györgyi Medical and Pharmaceutical Center, First      Department of Medicine, 
Hungary H-6720 Szeged, Korányi fasor 8-10
2University of Szeged, Faculty of Medicine, Albert Szent-Györgyi Medical and Pharmaceutical Center, Department         of Radiology, 
Hungary H-6725 Szeged, Semmelweis utca 6
Abstract
Non-Alcoholic Fatty Pancreas and Liver Disease (NAFPD and NAFLD) are often associated with Type 2 Diabetes Mel-
litus (T2DM). Our aim was to evaluate the incidence rate of NAFLD and NAFPD, the size of Pericardial Adipose Tissue (PAT) 
and the effect of metformin treatment on NAFLD, NAFPD and PAT in new-onset T2DM. 19 patients with new-onset T2DM and 
10 subjects as control group were involved. Computed tomography and laboratory tests were performed before the beginning of 
metformin therapy and 4 months afterwards. The PAT and the amount of fat in the pancreas and liver was determined by the X-
ray attenuation on unenhanced CT examination and compared with values for control subjects. Metabolic parameters improved 
significantly after the metformin therapy. The radiation absorption of the liver was significantly lower in patients with T2DM 
as compared to the control group (33.52±19.38 vs 53.1±8.31 HU) and significantly increased after the metformin therapy as 
compared to the baseline values (46.12±13.33 vs 33.52±19.38 HU). The radiation absorption of the pancreas was lower but 
not significant in patients with T2DM (32.76±9.55 vs 34.2±12.1 HU) and did not change significantly during the treatment 
(35.64±9.07 vs 32.76±9.55 HU). The size of the PAT was significantly larger in T2DM patients (2053.1±1136 vs 1223.9±312.9 
mm2) but did not change significantly after the treatment (2053.1±1136 vs 2026.2±1032 mm2). Metformin therapy decreased 
the amount of fat in the liver parallel with the improvement of the metabolic parameters and may be beneficial for the prevention 
of the late consequences of NAFLD.
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HOMA-IR: Homeostatic Model Assessment-Estimated 
Insulin Resistance
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Introduction
It is a well-known fact that insulin resistance and obesity 
cause fatty accumulation in many organs, including the liver [Non-
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Alcoholic Fatty Liver Disease (NAFLD)] and pancreas [Non-
Alcoholic Fatty Pancreas Disease (NAFPD)] [1]. The worldwide 
prevalence of NAFLD ranges widely from 6.3% to 33% with a 
median of 20%, depending on the kind of assessment methods 
[2-5]. There is a high prevalence of NAFLD in patients with Type 
2 Diabetes Mellitus (T2DM) (64-69%) [2,6-8] and dyslipidemia 
(20-81%) [9,10]. Obesity, type 2 diabetes mellitus and dyslipidemia 
are risk factors for the development of NAFLD [7,8,11,12]. The 
incidence rate of pre-DM is as high as 93.3% in NAFLD, so pre-
DM is a more important predictor of NAFLD than metabolic 
syndrome [13]. Moreover, it seems the male gender is presumably 
a further risk factor for NAFLD [2]. NAFLD may progress through 
steatohepatitis to cirrhosis and hepatocellular carcinoma [14,15]. 
NAFPD is a less well-studied phenomenon. Fatty pancreas is a 
common ultrasound finding with increased echogenicity of the 
parenchyma because of fat accumulation [16]. Previous studies 
suggested a 16-35% prevalence of fatty pancreas in the general 
population [17,18]. It seems that age [19], obesity, hyperglycemia 
and dyslipidemia are risk factors for NAFPD [18,20-22]. 
NAFPD may increase the risk for the development of 
metabolic syndrome by causing inflammation [23], impaired 
pancreatic beta cell function and hyperglycemia [24]. This 
relationship may explain the presence of T2DM [25] in 6.9-12.6% 
of patients with pancreatic steatosis [17,18]. Several studies 
suggested that insulin resistance is associated with pancreatic fat 
accumulation [20-22,26], Non-Alcoholic Steatohepatitis (NASH) 
[20,27] and pre-DM [21]. Higher pancreatic triglyceride content in 
obesity was described by proton magnetic resonance spectroscopy 
[28], CT [29-30] or MRI [31] even before the development of 
T2DM [28]. It was demonstrated that obesity leads to pancreatic 
ductal adenocarcinoma through pancreatic steatosis [23,32,33]. 
Evidence suggests that pancreatic steatosis has a role in T2DM, 
pancreatic exocrine dysfunction, acute pancreatitis [34,35], 
pancreatic cancer and the formation of pancreatic fistula after 
pancreatic surgery [36].
NAFLD and NAFPD are associated with each other because 
pancreatic fat is related to non-alcoholic steatohepatitis and is a 
significant predictor of the presence of NAFLD [37]. The elevation 
of liver transaminases may suggest the presence of NAFLD or 
NASH. Ultrasonography and transient elastography are currently 
the most appropriate imaging modality for NAFLD screening, and 
liver biopsy is the “gold standard” for characterizing liver histology 
in patients with NAFLD [38]. In contrast to liver, no biochemical 
marker is available for the diagnosis of NAFPD. Furthermore, 
as the pancreas is a retroperitoneal organ, pancreatic biopsy is 
more cumbersome to perform and may be accompanied by more 
sampling errors and complications as compared to liver biopsy. 
The visualisation of the pancreas by ultrasonography is more 
difficult, and the sensitivity and specificity of ultrasonography in 
detecting NAFPD are hampered by obesity and bloating.
Above all, in pre-diabetic and T2DM patients the amount of 
Pericardial Adipose Tissue (PAT) is significant higher compared to 
the amount of PAT in normoglycemic patients [39,40]. Previous 
review demonstrated that beside epicardial adipose tissue PAT is 
another risk factor for the development of cardiovascular disease 
in T2DM patients [41]. The aim of the present study was to 
evaluate the incidence rate of NAFLD and NAFPD, the size of 
PAT and the effect of metformin treatment on NAFLD, NAFPD 
and PAT in new-onset T2DM by measuring tissue attenuation and 
in unenhanced CT examinations.
Subjects and Methods
Nineteen patients with new-onset T2DM (male: 10; 
female: 9; mean age: 56.38±9.71 years; Body Mass Index (BMI): 
32.22±4.53 kg/m²) were involved in this prospective study. The 
control group comprised 10 subjects (male: 6; female: 4; mean 
age: 53.9±13.79 years; BMI: 30.0±4.72 kg/m²) without DM, 
matched for age, sex, BMI and serum lipids (Table 1), without 
the presence of any pancreatic, liver or cardiovascular disease or 
history of alcohol consumption. The diagnosis of T2DM was made 
in accordance with the American Diabetes Association criteria 
[42]. New-onset DM is defined as DM diagnosed within the last 
1 month before the date of enrolment. Patients only dieted and 
did not receive any hypoglycemic agent before inclusion and had 
not history of alcohol consumption. Exclusion criteria were any 
pancreatic, liver and cardiovascular disease, or inherited disorders 
of fat metabolism in the case history. Computed 
Control (male: 6; female: 4) T2DM (male: 10; female: 9) P values
Age (years) 53.9±13.79 56.38±9.71 p=0.631
BMI (kg/m²) 30.0±4.72 32.22±4.53 p=0.291
Serum cholesterol (mmol/l) 5.06±0.93 5.55±1.71 p=0.241
Serum triglyceride (mg/dl) 3.29±2.74 3.02±1.47 p=0.77
Data expressed as mean values ± standard deviation. T2DM: type 2 diabetes mellitus. BMI: body mass index.
Table 1: Age, BMI, cholesterol and triglyceride levels in patients with T2DM and control subjects.
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tomography and laboratory tests were performed as a measurement 
for serum triglyceride, cholesterol and insulin levels, fasting blood 
glucose and glycosylated hemoglobin (HbA1c), while Homeostatic 
Model Assessment-Estimated Insulin Resistance (HOMA-IR) was 
calculated before the beginning of 1000 mg metformin twice daily 
therapy and 4 months afterwards. 
The size of PAT and the amount of fat in the pancreas and 
liver was determined by X-ray attenuation rate on unenhanced CT 
examination [Hounsfield unit (HU)]. Each Region of Interest (ROI) 
in the liver, pancreas and spleen was a round area of approximately 
1.0 cm2 as a marker of the degree of attenuation [43]. In the case 
of PAT, measurements were performed in one dedicated slice at 
the junction of vena cava inferior and right atrium. ROIs were 
identified in Segment VII of the liver, along the diaphragmatic 
surface of the spleen and in the body of the pancreas. Mean density 
was calculated and General Electric Centricity PACS software was 
used to determine the values. NAFLD and NAFPD were defined 
when the liver-to-spleen or the pancreas-to-spleen attenuation ratio 
was <1 [44, 45]. All participants provided their written informed 
consent. The study protocol was in full accordance with the most 
recent revisions of the Helsinki Declaration and was approved by 
the ethics committee at the University of Szeged. Paired-samples 
and 2 samples t-tests were used to describe the differences between 
the laboratory values and X-ray attenuation rate at the beginning of 
metformin therapy and 4 months afterwards. Data were processed 
with SPSS 22.0 (Armonk, New York, USA) and a level of p<0.05 
was considered statistically significant.
Results
Fasting blood glucose, HbA1c, serum insulin and HOMA-IR 
decreased significantly after the metformin therapy as compared to 
the baseline values (Table 2). However, serum triglyceride and BMI 
did not change. In total, 6 patients (31.6%) received statin therapy 
for elevated cholesterol and triglyceride levels. Nevertheless, the 
serum cholesterol level decreased significantly in those patients 
who did not receive statin therapy in addition to the metformin 
therapy (p=0.016) (Table 2).
Baseline
 values
4 months
 afterwards P values
Fasting blood 
glucose (mmol/l) 11.75±5.12 6.69±1.21 p=0.001
HbA1c (%) 9.22±2.56 6.48±0.73 p<0.001
Serum insulin 
(mU/l) 34.4±21.11 23.0±13.46 p=0.005
HOMA-IR (molar 
units) 16.88±10.07 6.56 b p<0.001
Serum cholesterol 
without statin 
therapy (mmol/l)
4.81±1.25 4.44±1.09 p=0.016
Serum triglyceride 
(mg/dl) 2.77±1.33 2.34±1.43 p=0.209
BMI (kg/m²) 32.01±4.62 31.85±4.58 p=0.407
Data expressed as mean values±standard deviation. HbA1c: 
glycosylated hemoglobin. HOMA-IR: homeostasis model 
assessment-estimated insulin resistance. BMI: body mass index.
Table 2: The changes of laboratory test results and BMI from baseline 
values to 4 months afterwards.
Thirteen patients (68.4%) had NAFLD based on the diagnostic 
criteria [44]. We compared the group with NAFLD and the group 
without NAFLD. A significant relationship was not found between 
BMI, triglyceride, fasting blood glucose level, HbA1c and liver 
enzymes. However, a significant link was revealed between groups 
in serum cholesterol levels (p=0.002) (Table 3).
Patients 
with NAFLD
Patients 
without
 NAFLD
P values
Serum cholesterol 
(mmol/l) 5.54±1.14 5.78±0.28 p=0.002
Serum triglyceride 
(mg/dl) 2.77±1.26 2.88±1.54 p=0.881
BMI (kg/m²) 32.21±4.36 29.19±5.62 p=0.163
Aspartate 
aminotransferase 
(U/l)
20.88±5.30 16.50±3.00 p=0.100
Alanine 
aminotransferase 
(U/l)
26.50±9.62 19.50±6.45 p=0.171
Alkaline 
phosphatase (U/l) 79.25±21.02 83.50±24.35 p=0.777
Gamma 
glutamyltransferase 
(U/l)
42.38±17.66 46.25±25.61 p=0.896
Total bilirubin 
(μmol/l)
7.51±1.95 5.85±2.54 p=0.303
Fasting blood 
glucose (mmol/l) 11.48±4.97 12.25±9.2 p=0.782
HbA1c (%) 9.25±2.3 9.2±2.8 p=0.944
HOMA-IR 19.15±9.77 11.42±9.48 p=0.169
Data expressed as mean value ± standard deviation. NAFLD: non-
alcoholic fatty liver disease. BMI: body mass index.
Table 3: The cholesterol, triglyceride, BMI, fasting blood glucose, HbA1c 
and liver enzyme values in patients with and without NAFLD.
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The radiation absorption of the liver was significantly lower in 
patients with T2DM as compared to the control group [33.52±19.38 
HU versus 53.1±8.31 HU (p=0.001)] and significantly increased 
after the metformin therapy as compared to the baseline values 
[33.52±19.38 HU versus 46.12±13.33 HU (p=0.039)] (Figure 1). 
Only 8 patients (42.1%) had NAFLD after the 4-month metformin 
therapy according to the the diagnostic criteria.
The X-ray attenuation rate during a native CT examination was measured 
in new-onset type 2 diabetic patients before and 4 months after the start of 
metformin therapy and in control subjects. Data expressed as mean values 
± standard deviation. HU: Hounsfield Unit. *p < 0.05.
Figure 1: The radiation absorption of the liver.
Fifteen patients (78.9%) were diagnosed with NAFPD 
based on the diagnostic criteria. The radiation absorption of the 
pancreas was lower but not significant in patients with T2DM as 
compared to the control group [32.76±9.55 HU versus 34.2±12.1 
HU (p=0.755)] and did not change significantly after the treatment 
[32.76±9.55 HU versus 35.64±9.07 HU (p=0.405)] (Figure 2).
The X-ray attenuation rate during a native CT examination was measured 
in new-onset type 2 diabetic patients before and 4 months after the start 
of metformin therapy and in control subjects. Data expressed as mean 
values±standard deviation. HU: Hounsfield Unit.
Figure 2: The radiation absorption of the pancreas.
The size of the PAT was significantly larger in patients with 
T2DM as compared to the control group [2053.1±1136 versus 
1223.9±312.9 mm2 (p=0.01)] and did not change significantly 
after the metformin treatment [2053.1±1136 versus 2026.2±1032 
mm2 (p=0.86)] (Figure 3). The present study has demonstrated that 
NAFLD and NAFPD is already present in patients with new-onset 
diabetes. Metformin therapy effectively decreased the amount of 
fat in the liver, but not in the pancreas. PAT is larger in new-onset 
T2DM as compared to the control group and it is not influenced by 
metformin treatment.
A native CT examination was measured in new-onset type 2 diabetic 
patients before and 4 months after the start of metformin therapy and in 
control subjects. Data expressed as mean values±standard deviation. mm2: 
square millimeters. *p < 0.05.
Figure 3: The size of pericardial adipose tissue.
Discussion
NAFLD is the most common liver disorder worldwide 
and contributes significantly to overall mortality, as well as to 
cardiovascular and liver-related mortality in particular. The main 
risk factor is T2DM; NAFLD can be demonstrated in 64-69% of 
type 2 diabetic patients [2,6-8]. It is likely that NAFLD is the hepatic 
manifestation of metabolic syndrome, where insulin resistance is 
the main risk factor [46]. On the other hand, NAFLD may progress 
to its inflammatory complication, NASH. The high incidence of 
NASH in patients with T2DM leads to further complications, such 
as liver cirrhosis and hepatocellular carcinoma [14,15]. Given the 
expected rise in the prevalence of T2DM, NAFLD is projected to 
be the principal aetiology for liver transplantation within the next 
decade [47]. Furthermore, NAFLD is thought to be an independent 
determinant of cardiovascular disease [48].
PAT plays a role in myocardial energy metabolism through 
the connection with the coronary arteries and the myocardium 
[49]. Increased pericardial fat volume was demonstrated as a 
risk factor for coronary artery disease [50] and the development 
of cardiovascular disease in T2DM patients [41]. Lozzo found 
increased PAT volume in T2DM patients [51]. Previous study 
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evaluated the effect of pioglitazone and metformin therapy on 
PAT resulting in an increased pericardial fat volume during the 24-
week long pioglitazone treatment [52]. However, metformin did 
not change significantly the size of PAT [52]. Metabolic syndrome 
and obesity are commonly associated with NAFLD. However, 
the links between NAFLD and insulin resistance and T2DM 
are not fully understood [47]. NAFLD can predict the incidence 
of diabetes independently of traditional risk factors, including 
obesity, peripheral insulin resistance and metabolic syndrome 
[53]. Moreover, diabetes promotes or worsens hepatic steatosis, 
thus fueling a vicious cycle.
The T2DM patient cohort was selected to study the effect 
of insulin resistance on the prevalence of NAFLD. The control 
subjects did not have DM, the presence of any pancreatic, liver 
or cardiovascular disease or history of alcohol consumption, but 
were matched for age, sex, BMI and serum lipids. Therefore, the 
presence of T2DM was the only variable in our study that could 
influence the prevalence of NAFLD. Patients with new-onset DM 
diagnosed within one month, and without alcohol consumption, 
any pancreatic, liver and cardiovascular disease, or inherited 
disorders of fat metabolism in the case history were enrolled in our 
prospective study: 
To analyse the effect of early-phase insulin resistance on the •	
development of NAFLD and NAFPD 
To study patients without antidiabetic medication; and •	
To analyse the effect of newly-introduced metformin therapy •	
on the degree of fat content in the liver, pancreas and on the 
size of PAT.
69% and 62% of T2DM patients had NAFLD defined by 
ultrasound in two studies, respectively [7, 8], and in the latter study 
87% of the NAFLD cases were confirmed histologically. However, 
these studies had a cross-sectional design that included diabetic 
patients with variable disease length. We involved new-onset DM 
patients diagnosed within 1 month before the time of enrolment 
in our study. It was demonstrated that insulin resistance is already 
present at least 5 years before overt diabetes in populations with a 
high prevalence of T2DM [54]. 68.4% of newly diagnosed diabetic 
patients in our study had NAFLD. This means that NAFLD is 
already present in the early phase of DM. The high prevalence of 
NAFLD in our study can be explained by the fact that our patients 
had several risk factors. They were overweight and had elevated 
cholesterol and triglyceride levels. However, the BMI, serum 
cholesterol and triglyceride levels were also above the norm in the 
control group, and there were no significant differences between 
the control group and the DM group. In contrast, only 10% of the 
control subjects had NAFLD. Furthermore, the radiation absorption 
of the liver was significantly lower, indicating an increased amount 
of fat in the liver in patients with T2DM as compared to the control 
group. This increased amount of fat, therefore, can be attributed 
to insulin resistance after excluding other risk factors. The high 
prevalence of NAFLD can also be explained by the fact that we 
defined fatty liver by measuring radiation absorption on computed 
tomography, which is more sensitive, specific and operator-
independent as compared to ultrasound.
NAFPD has been poorly investigated as compared to 
NAFLD, although interest is increasing among researchers. 
Reports on the relationship between NAFPD and β-cell function 
are inconsistent, however. Some studies indicate that pancreatic 
lipid content is negatively associated with insulin secretion in 
nondiabetic subjects [55] or individuals with prediabetes [56], 
while others suggest that there is no relationship between β-cell 
function and pancreatic fat in prediabetic [57] or diabetic subjects 
[55]. Pancreatic fat content can be studied with multiple diagnostic 
modalities. A histological examination requires a pancreatic biopsy, 
but this is invasive and there are complications associated with 
it. Ultrasonography is cheap and easily available, but a relatively 
insensitive measure of pancreatic fat content. More recently, 
expensive MRI techniques have been utilized for the assessment 
of pancreatic fat deposition. A native CT scan was employed in our 
study to measure the amount of pancreatic steatosis using radiation 
absorption correlated to the spleen. Diabetic patients have been 
demonstrated to have higher pancreatic fat content measured by 
magnetic resonance spectroscopy [55,58] and dual-echo magnetic 
resonance chemical shift imaging [59]. In contrast, Saisho et al. 
found that pancreatic fat content was not significantly increased in 
T2DM [60]. 78.9% of new-onset DM patients were diagnosed as 
having NAFPD based on the diagnostic criteria, while no NAFPD 
was detected in the control population in our study. 
Since the control group was matched for age, sex, BMI 
and serum lipids with the T2DM group, NAFPD may be a 
consequence of insulin resistance. Newly (<1 month) diagnosed 
T2DM patients were enrolled in the study to assess the effect 
of metformin on NAFLD and NAFPD. Metformin is the first-
line agent for the treatment of diabetes and is the most popular 
antidiabetic agent. The effects of metformin on NAFLD have 
been evaluated in several studies, some of them showing a 
beneficial effect on aminotransferase levels or liver histological 
alterations [2,61-63]. No study has ever evaluated the effect of 
metformin on hepatic fat content measured by tissue attenuation 
on unenhanced CT examination. Four-month-long metformin 
treatment significantly reduced fat content in the liver in our study. 
Metformin also improved glycemic control and insulin resistance 
measured by HOMA-IR, and reduced serum cholesterol level, 
which can be partly attributed to its beneficial effect. However, 
metformin therapy reduced pancreatic fat content and the size of 
PAT but not significantly. NAFLD and NAFPD can be detected 
in the majority of new-onset T2DM patients. Metformin therapy 
decreased the amount of fat in liver parallel with the improvement 
of the metabolic parameters, but not in the pancreas and did not 
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reduce the size of PAT. Metformin therapy started early in the 
course of diabetes may be beneficial for the prevention of the late 
consequences of NAFLD.
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